Please assess the completion status of the following clinical trial:

Trial Title: Colchicine to Prevent Post-Pericardiotomy Syndrome and Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All consecutive adult patients (age \> 40) undergoing standard (non-minimally invasive) coronary artery bypass surgery and/or aortic valve surgery will be approached for enrollment.~* All patients must be able to provide informed consent and comply with the 3 month follow-up.~* For women of reproductive capability, contraception is necessary and required.~Exclusion Criteria:~* Epidermal growth factor receptor (eGFR) \< 30 mL/min/1.73 m\^2, serum creatinine \> 2.5 mg/dL or requiring dialysis~* Known permanent or current atrial fibrillation (history of paroxysmal atrial fibrillation allowed if in sinus rhythm at present)~* Allergy to colchicine or already treated with colchicine.~* Known blood dyscrasia (acute or chronic leukemia, pancytopenia, aplastic anemia, leukopenia)~* Known serious gastrointestinal disease~* Known severe liver disease (cirrhosis, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \> 2x the upper limit of normal, Model End Stage Liver Disease (MELD) score \> 20)~* Women of childbearing potential not using contraception.~* Patients with HIV or AIDS as the use of protease inhibitors can result in serious colchicine toxicity.~* Patients who are treated with strong CYP3A4 inhibitors (clarithromycin/erythromycin, chloramphenicol, ketoconazole/itraconazole, and nefazodone).~* There is a risk of rhabdomyolysis with the use of digoxin and colchicine, we will exclude patients who require ongoing treatment with digoxin.~* Inability or unwillingness of the individual to give written informed consent.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): A placebo pill (identical to the study drug Colchicine) will be given in a double-blinded fashion to study participants randomized to placebo.
- Colchicine (Type: EXPERIMENTAL): Colchicine 0.6mg bid will be given to study participants randomized to the study drug arm beginning at 48-72 hours prior to the planned cardiac surgery and then continued for a total of 30 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).